Last reviewed 2026-04-22 · How we verify

CD0271 0.1% / CD1579 2.5%

CD0271 and CD1579 are topical agents that work synergistically to reduce skin inflammation and improve dermatological conditions through complementary anti-inflammatory pathways.

CD0271 and CD1579 are topical agents that work synergistically to reduce skin inflammation and improve dermatological conditions through complementary anti-inflammatory pathways. Used for Dermatological inflammatory condition (specific indication not publicly disclosed).

At a glance

Mechanism of action

This is a fixed-dose combination topical product in development by Galderma for dermatological use. CD0271 and CD1579 are combined at specific concentrations (0.1% and 2.5% respectively) to provide enhanced therapeutic efficacy. The exact molecular targets and mechanisms require proprietary information from Galderma's development program.

Approved indications

• Dermatological inflammatory condition (specific indication not publicly disclosed)

Common side effects

No common side effects on file.

Key clinical trials

• A Pilot Study to Investigate Filiation Between Primary and Secondary Lesions in Acne Patients (PHASE1)
• Multi-center, Randomized, Double-blind Efficacy and Safety of CD0271 0.3%/CD1579 2.5 % Topical Gel in Acne Vulgaris (PHASE3)
• Efficacy and Safety Study of GK530G Versus CD0271 0.1% Gel and CD1579 2.5% Gel in the Treatment of Acne Vulgaris. (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• CD0271 0.1% / CD1579 2.5% CI brief — competitive landscape report
• CD0271 0.1% / CD1579 2.5% updates RSS · CI watch RSS
• Galderma R&D portfolio CI